Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SynAct Pharma AB ( (SE:SYNACT) ) has provided an update.
SynAct Pharma is convening investors, analysts and media for a Capital Markets Day in Stockholm on March 11, positioning its resolution therapy platform at the center of upcoming clinical and strategic milestones. The event underscores the company’s shift into a transformational phase, with Phase 2b data in newly diagnosed severe rheumatoid arthritis expected in the second quarter and an expanding pipeline in viral-induced inflammation.
During the Capital Markets Day, management and external clinical experts will detail the mechanisms and market potential of SynAct’s lead candidate resomelagon, as well as its respiratory infection program, including the RESPIRE trial. The agenda also features sessions on market overviews and potential deal scenarios, signaling a focus on partnering and business development that could materially influence SynAct’s future funding, commercialization path and industry positioning.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation by selectively activating the melanocortin system. Its portfolio of oral and injectable melanocortin agonists targets anti-inflammatory and inflammation resolution mechanisms, aiming to restore immune balance for patients with severe inflammatory conditions such as rheumatoid arthritis and viral-induced inflammation.
Average Trading Volume: 138,007
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.01B
For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.